Background: Our laboratory has shown that inhalational sensitization to new antigens is facilitated through an ongoing T H 2-polarized inflammation of the lung, a phenomenon we call ''collateral priming.'' Objective: We were interested to analyze whether a T H 1-polarized pulmonary inflammation also facilitates priming toward new antigens and which cytokine or cytokines are involved. Methods: T H 1-polarized T cells were generated in vitro and transferred into congenic mice. Mice were challenged initially with cognate antigen and an unrelated antigen; consecutively, they received cognate antigen or the secondary antigen. Airway inflammation, antigen-specific IgG2a levels, and airway hyperresponsiveness were assessed to determine the inflammatory phenotype, with antibody blocking studies used to determine cytokine requirements for T H 1 collateral priming. Results: Our experiments revealed that ongoing inflammation of the lung induced by the transfer of T H 1-polarized cells also facilitates priming toward new antigens, which results in lymphocytic inflammation of the lung. Interestingly, blocking studies identified IL-17A as a major contributor to this pathology. Accordingly, we could demonstrate for the first time that T H 17-polarized cells alone can facilitate priming toward new antigens, inducing lymphocytic airway inflammation and strong airway hyperresponsiveness. Flow cytometric analysis revealed priming of endogenous T cells for IL-17A secretion with a distinct memory/effector phenotype compared to T H 1 cells, thus presenting an exciting model to further elucidate differentiation of T H 17 cells. Conclusions: We show that airway inflammation mediated by T H 17 cells facilitates sensitization to new antigens and confers
A wealth of animal data supports the pivotal role of T H 2-polarized T cells in the initiation and propagation of allergic airway disease. 1 Yet some murine studies suggest a less unequivocal situation with regard to the role of T H 1 polarization in allergic airway disease. Some murine data show a clear-cut effect of T H 1-polarized immune responses in inhibiting T H 2-polarized airway disease, 2, 3 and other studies show a significant exacerbation by T H 1 cells. 4, 5 The expansion of the T H 1/T H 2 dichotomy to include a new distinct cell type, T H 17 cells, 6 has added more complexity to this question. IL-17A has been shown, in different chronic inflammatory diseases, to underlie effects formerly ascribed to T H 1 cytokines. 7 In the context of (allergic) airway inflammation, IL-17A has been described to promote different aspects of the disease [8] [9] [10] [11] [12] but might also play a protective role. 13 Studies in human subjects have generally been less clear cut with regard to the T H 1/T H 2 polarity of allergic airway disease. Many studies have found that both T H 1 and T H 2 cytokine levels are increased in the blood and airways of asthmatic patients, [14] [15] [16] with T H 1 cytokine levels correlating with disease severity, and similar data have been obtained for IL-17A. 17 Additionally, human studies, particularly in childhood, point to a role of T H 1-polarized viral infections in the promotion of allergic airway disease. [18] [19] [20] These data, some of which have been translated into murine models, 21 clearly dispute the hygiene hypothesis. 22 These controversies show that the immunologic effects of a concomitant airway inflammation on subsequent immune responses to unrelated antigens, such as aeroallergens, remain controversial or unknown. We therefore initially sought to address the question of how a T H 1-polarized airway inflammation influences subsequent sensitizations toward neoantigens.
We have recently described a model showing that ongoing T H 2-polarized airway inflammation facilitates priming toward secondary unrelated allergens. 23 We therefore sought to delineate whether similar mechanisms also promote T H 1-polarized airway responses. We show here that ongoing airway inflammation induced by the transfer of T H 1-polarized T cells also facilitates pulmonary priming toward a secondary unrelated antigen. Surprisingly, T H 1-induced collateral priming was not dependent on IFN-g but does depend on IL-17A. Analysis of the transferred T H 1 cells revealed a small IL-17A-producing population of antigen-specific CD4 1 
METHODS Mice
BALB/cJ (wild-type) mice, T-cell receptor-transgenic OT-II mice (C57BL/ 6-Tg [TcraTcrb]425Cbn/J on a C57/Bl6 background), and IFN-g receptordeficient mice (B6.129S7-Ifngr1tm1Agt/, C57/Bl6 background) were purchased from the Jackson Laboratory (Bar Harbor, Me). T-cell receptortransgenic DO11.10 mice (C.Cg-Tg[DO11.10]10Dlo/J) backcrossed onto an ab 2/2 background were bred in our facility. Six-to 10-week-old female mice were used in all experiments. All experimental methods described in this article were performed as approved by the respective institutional animal care and use committees. 
Collateral priming protocol
For primary challenge, 24 hours after the transfer of T H cells, mice were exposed to either 5 mg of ovalbumin (OVA; grade V; Sigma-Aldrich, St Louis, Mo) and 5 mg of BSA (fraction V; Invitrogen, Carlsbad, Calif) or keyhole limpet hemocyanin (KLH; Sigma-Aldrich) intranasally on days 0 and 1. Secondary challenge was performed with either 5 mg of OVA or BSA or KLH on days 18 and 19. Mice were killed on day 22 (Fig 1, A) . For induction of memory, rechallenge was applied on days 74 and 75, with doses as used for secondary challenges.
Analysis of lung function
Mice were anesthetized and intubated orotracheally for lung function measurements, as described previously. 24 AHR was assessed based on increases in lung resistance during provocation with increasing doses of aerosolized methacholine defined by means of a feedback-dose control system. 25 
Antibody treatment
For blocking studies against IFN-g (clone XMG1.2) or IL-17A (clone 50104.11; R&D Systems, Minneapolis, Minn), mice were treated with 100 mg of anti-IFN-g intraperitoneally on days 21, 0, 1, 2, and 3 or with 50 mg of anti-IL-17A intraperitoneally and intranasally on days 0, 1, 2, and 3 of the collateral priming protocol (Fig 1, A) 1 hour before primary antigen application.
Analysis of bronchoalveolar lavage fluid
Bronchoalveolar lavage (BAL) inflammatory cells were obtained by means of lavage of the airway lumen with PBS, prepared, stained, and differentiated microscopically, as previously described. 26 
Determination of serum antibody concentration
Antigen-specific (KLH, BSA, and OVA) antibodies in sera were determined by means of ELISA, as described previously. 26 Lymph node and lung cell preparation and restimulation
Mediastinal lymph nodes (mLNs) and lungs were harvested on days 4 or 22 of the collateral priming protocol (Fig 1, A) and pooled from each group at the time of death. Single-cell suspensions were obtained as described previously. 26 Cells harvested on day 22 were stimulated immediately, whereas cells harvested on day 4 were stimulated after a predetermined 4-day resting period.
Restimulation was performed with 1 mg/mL phorbol 12-myristate 13-acetate (PMA; Sigma-Aldrich) and 0.75 mg/mL ionomycin (Sigma-Aldrich) for 4 hours (Figs 3, A and B, and 5, A and B, and see Figs E5, A, and E6, A, in this article's Online Repository at www.jacionline.org), with 5 mg of OVA peptide and freshly isolated APCs (Fig 2, A) , 200 mg/mL OVA, BSA, or KLH for 48 hours (Figs 2, B, and 3, C) or with GM-CSF differentiated bone marrow-derived dendritic cells from wild-type mice and 200 mg/mL OVA, KLH, or medium for 48 hours (Fig E6, B) . For intracellular cytokine staining, GolgiPlug was added to PMA and ionomycin stimulation, according to the manufacturer's instructions (BD Biosciences, Mississauga, Ontario, Canada), for 4 hours (Figs 3, A, and 5, A).
Measurement of cytokine production
The cytokines IL-2, IL-4, IL-5, IL-6, IL-10, IL-13, IL-17, IFN-g, and TNFa were measured by using Multiplex-based bead technology (Millipore, Temecula, Calif; 
Determination of statistical significance
Statistical significance was determined by using the Mann-Whitney U test, unless otherwise stated. A P value of less than .05 was considered significant. Unless indicated otherwise, 5 mice were used for each condition studied in an individual experiment. Each treatment condition was repeated at least 3 times.
RESULTS

Phenotype of T H 1 collateral priming
To test our hypothesis that collateral priming is a phenomenon that pertains not only to T H 2-polarized airway inflammation, we adapted our model for T H 2 collateral priming 23 to a T H 1-polarized response (Fig 1, A) . This model allowed Eisenbarth et al 23 to determine that an ongoing T H 2-polarized airway inflammation facilitates sensitization toward a secondary unrelated antigen.
The collateral priming model consists of the transfer of polarized transgenic DO11.10 T cells and 2 airway challenges. A first airway challenge is performed with the cognate antigen OVA together with a secondary unrelated antigen (BSA or KLH). After the initial antigen-driven inflammation has resolved, we challenged a second time with either cognate antigen or the secondary unrelated antigen (Fig 1, A) . Comparing the transfer of T H 2-polarized T H cells with the transfer of T H 1-polarized T H cells, we observed that a secondary challenge (''second: K'') with an unrelated antigen, KLH, introduced during the first challenge with the cognate antigen OVA (''first: O1K'') facilitates priming toward this antigen, regardless of the polarization (transfer T H 1 vs T H 2) of the transferred T cells (Fig 1, B) . The dose of the secondary antigen alone is not sufficient to induce significant airway inflammation (''first: K, second: K'').
Obviously the composition of the BAL inflammatory influx differs when transferring T H 1 versus T H 2 cells. T H 2 collateral priming induces a typical T H 2-polarized airway inflammation, while T H 1 collateral priming induces an inflammatory influx that is dominated by lymphocytes and cells of monocytic morphology (Fig 1, B) . Transfer of naive transgenic T cells followed by 2 consecutive OVA challenges or transfer of T H 1-polarized transgenic T cells and primary challenge with PBS followed by challenge with OVA during secondary challenge did not result in significant airway inflammation (see Fig E1, B, in this article's Online Repository at www.jacionline.org), demonstrating that activation of the transferred, polarized T-cell population and the ensuing inflammation are necessary for collateral priming to occur.
The increase in levels of KLH-specific IgG2a antibodies in peripheral blood (Fig 1, C) confirmed the induction of a T H 1-polarized, systemic KLH-specific antigen response. Finally, rechallenge 8 weeks after initial priming demonstrated that collateral priming induces sustained memory formation (see Fig E1, A) .
Independence of T H 1 collateral priming from IFN-g
We carefully examined the cytokine profile of our transferred T H 1 cells before transfer and the cytokine profile of mLN cells Fig 2, D) . B, BSA; 1st, first challenge; ns, not significant; O, OVA; 2nd, second challenge. Experiments were performed 3 to 4 times. (Fig 3, A) and supernatant ELISA levels (Fig 3, B) of IL-17A and IFN-g production from in vitro polarized T H 1 cells (gray, IFN-g; black, IL-17A). C, Multiplex analysis of IL-17A production as in Fig 2, B. n.d., Not detectable (duplicates). D and E, BAL cells and KLH-specific serum IgG2a levels from mice undergoing the T H 1 collateral priming protocol receiving IL-17A-neutralizing antibody (treatment). 1st, First challenge; K, KLH; O, OVA; 2nd, second challenge. n 5 5 animals per group. *P < .05. ***P < .001. Experiments were performed 3 to 5 times. upon restimulation after transfer to identify possible mediators responsible for the T H 1 collateral priming phenomenon. As expected, in vitro restimulation of T H 1 cells with OVA peptide and APCs elicited a typical T H 1 profile: large amounts of IFN-g; some IL-2, IL-10, and TNF-a; and negligible amounts of IL-4, IL-5, IL-6, and IL-13 compared with cells polarized toward a T H 2 phenotype (Fig 2, A) . The ex vivo cytokine profile of mLN cells upon in vitro restimulation after an initial intranasal challenge also revealed a typical T H 1 profile (Fig 2, B) .
In spite of a predominance of IFN-g, blocking studies with an anti-IFN-g antibody showed that T H 1 collateral priming is independent from the presence of IFN-g. Administration of anti-IFN-g antibody during the first antigen challenge did not diminish T H 1 collateral priming (Fig 2, C) . Similar results were obtained in an OT-II transfer system comparing wild-type with IFN-g receptor-deficient mice as acceptor mice in the collateral priming protocol (Fig 2, D) .
IL-17A is a potent mediator of T H 1 transfermediated collateral priming
Consecutively, we extended our search for possible mediators of T H 1 collateral priming. We included IL-17A in our analysis, considering that in some studies T H 17 cells have replaced T H 1 cells as principal culprits in certain diseases. 7, 27 In vitro analyses of T H 1-polarized transgenic cells by means of intracellular cytokine staining revealed that among the transgenic T-cell population, we could identify a distinct IL-17A-producing population (Fig 3, A) . Although IL-17A-producing T cells represented only a small population compared with IFN-g-producing cells, considerable amounts of IL-17A were secreted during restimulation, as determined by means of ELISA (Fig 3, B) . Additionally, OVA-specific in vitro restimulation of mLN cells after the first antigen challenge revealed significant amounts of IL-17A in the culture supernatants (Fig 3, C) . Thus we identified a small population of IL-17A-producing antigen-specific CD4 1 cells in our T H 1-polarized cultures. These results encouraged us to test whether IL-17A might be a decisive mediator for T H 1 collateral priming.
Administering an anti-IL-17A antibody intraperitoneally and intranasally on days 0 to 3 during the first antigen challenge, we observed a significant reduction in T H 1 collateral priming, based on a significant reduction in BAL cell counts (Fig 3, D) , as well as a significant reduction in KLH-specific IgG2a levels in peripheral blood (Fig 3, E) .
IL-17A-secreting cells confer collateral priming in vivo
Because our results revealed IL-17A and not IFN-g as an important mediator in collateral priming, we sought to investigate whether the effects observed by T H 1 cell transfer would be similar when transferring IL-17A-producing T H 17 cells. To this end, we performed the collateral priming protocol (Fig 1, A) with in vitro T H 17-polarized DO11.10 cells. Analysis of the BAL fluid after the second airway challenge showed that priming toward the unrelated antigen KLH was facilitated by T H 17 cell transfer. T H 17-polarized collateral priming led to an influx of monocytes and numerous lymphocytes into the airways (Fig  4, A and B) , resembling the BAL differential observed in T H 1 collateral priming. Systemic sensitization toward the secondary antigen was confirmed by the induction of KLH-specific IgG2a antibodies (Fig 4, C) . Finally, T H 17 collateral priming led to significant AHR compared to that seen in control mice (Fig 4, D (Fig 5, A, and see Fig E5) . ELISA measurements of IL-17A versus IFN-g secretion in the supernatants of lung and LN cells (Fig 5, B) confirmed the intracellular cytokine data in that they also revealed significant secretion of IL-17A and IFN-g in restimulated lung cells, with secretion of these cytokines in restimulated LN cells being less than the detections limits of the ELISAs. Direct comparison of IL-17A and IFN-g secretion by lung and LN cells that were restimulated either nonspecifically with PMA/ionomycin or specifically with antigens (OVA/KLH in the presence of bone marrow-derived dendritic cells) revealed a similar pattern and confirmed priming toward KLH (see Fig E6 in this article' s Online Repository at www.jacionline.org) because KLHspecific IL-17A, as well as IFN-g, production could be demonstrated (see Fig E6, inter-low cells, thus resembling effector memory cells (Fig 5, C, and see Fig E5) . Moreover, IL-17A-producing lung cells express CD62L in higher amounts compared with the IFN-g-producing population, regardless of central memory or the effector memory phenotype (Fig 5, D) .
DISCUSSION
Our current study extends previous findings demonstrating that an ongoing T H 2-polarized pulmonary inflammation facilitates priming toward unrelated antigens. 23, 26, 29, 30 We identify IL-17A as the key cytokine to facilitate priming toward new antigens during concomitant T H 1-polarized airway inflammation and demonstrate that T H 17 cells by themselves can facilitate priming of endogenous T cells for IL-17A production. IL-17A seems to be a major contributor to both T H 1 and T H 17 collateral priming: neutralization of IL-17A in T H 1 (Fig 3, D) and T H 17 (see Fig E7 in this article's Online Repository at www.jacionline.org) collateral priming significantly reduces BAL inflammatory cell influx, suggesting that IL-17A is an important contributor to the collateral priming process under both circumstances. However, neutralization of IL-17A during cell transfer and the first challenge phase did not affect T H 2 collateral priming (see Fig E7) .
Human studies show that exacerbation and chronicity of asthma are linked to T H 1-polarized pulmonary inflammation, which often occurs because of viral infections, [18] [19] [20] 31 thus underlining an important role not only for T H 2-but also T H 1-polarized lymphocytes in asthmatic patients. Our results revealed that collateral priming can be induced through transfer of T H 1-polarized cells, possibly modeling the increased risk of allergic sensitization after viral infections seen in children. [18] [19] [20] However, in spite of the importance of IFN-g as the key T H 1 cytokine, T H 1 collateral priming depends on IL-17A. Since the paradigm of a T H 1/T H 2 dichotomy in inflammatory disorders has been revised to include T H 17 cells, a wealth of data has been generated linking these cells to deleterious effects that were previously thought to be T H 1-driven diseases.
7,27,32,33 Additionally, a critical role of (Fig 5, A) and ELISA supernatant analysis (Fig 5, B) for IL-17A and IFN-g secretion from CD4 1 cells of lung/LN cultures from control mice (nil/O1K/O) and mice subjected to collateral priming (Th17/O1K/K). C and D, CD44 and CD62L surface expression (Fig 5, C) J ALLERGY CLIN IMMUNOL VOLUME 128, NUMBER 1 T H 17 cells in host defense, including viral infections, has been demonstrated. 34, 35 In patients with allergic airway disease, IL-17A levels correlate with disease severity and the influx of neutrophils. [36] [37] [38] Rodent models of allergic airway inflammation revealed a role for IL-17A in the recruitment of neutrophils, as well as eosinophils, 10, 39 and complement factor C3a as an important regulator of the IL-23/T H 17 axis in patients with severe asthma. 40 Our studies confirm the crucial role of T H 17 in pulmonary priming for airway inflammation and reactivity and thus underline the need to address these cells in more detail when searching for new interventional strategies in patients with allergic airway disease.
The development of an IL-17A-producing subpopulation of CD4 1 cells under T H 1-polarizing conditions was surprising because IFN-g is described to counterbalance T H 17 polarization. 41 However, in light of in vivo circumstances in which developing T H 17 cells might encounter IFN-g and other cytokines favoring or opposing T H 17 cell development, the presence of a minor IL-17A-producing population that is not susceptible to IFN-g suppression is not inconceivable. In fact, our own in vivo data on cytokine secretion by lung and LN cells after the secondary challenge in T H 17 collateral priming (Fig 5, A and B) showed secretion of IL-17A and large amounts of IFN-g by distinct populations of lung cells, suggesting that T H 17 cells can escape the suppressive effects of IFN-g during their development. Indeed, studies have suggested that under certain circumstances, the presence of IL-17A might even be important for recruitment of T H 1 cells in patients with bacterial infections. 42 Because IL-17A, in contrast to IL-4, which was identified as a crucial cytokine for T H 2 collateral priming, is not directly acting as a T-cell differentiation factor, the mechanism behind IL-17A-mediated collateral priming might be more indirect. Various cell types, including bronchial epithelial cells and fibroblasts, are described to secret chemokines and cytokines (eg, T H 17 differentiation factor IL-6) and upregulate leukocyte adhesion molecules, such as intercellular adhesion molecule 1, in response to IL-17A stimulation. 43 Together with the presence of other inflammatory cells during the first challenge phase, such as macrophages, 44 which under inflammatory conditions have been described to be sufficient for T H 17 polarization of naive T cells, this might provide a milieu sufficient for T H 17 differentiation.
Contrary to some studies that point toward a pivotal role of IL-17A in neutrophilia, 10, 34, 45 we found a lymphocytic influx into the BAL fluid on day 22 after T H 17 collateral priming with few neutrophils. This discrepancy might depend on different protocols for the induction of airway inflammation, in particular with regard to the amount of antigen used. Higher amounts of antigen invariably increase the amount of antigen-contaminating LPS, which dose dependently induces neutrophilia. 46 Additionally, analysis of BAL cells at different time points after challenge revealed that neutrophils appear in the lung 24 hours after the first challenge phase (day 4), as well as 24 hours after the second challenge phase (day 20), but decrease in number with time, as seen at 72 hours after the second challenge (day 22), suggesting that early neutrophilia might be missed in our protocol (see Fig E8 in this article' s Online Repository at www.jacionline.org). Recent clinical data also suggest a role for IL-17A (and IL-17F) in patients with chronic obstructive pulmonary disease and asthma but show no correlation with neutrophilic airway inflammation. 47 Several studies have shown a seminal role for the IFN-g/IL-12 axis in the induction of AHR, 48, 49 whereas other studies demonstrate contribution of the T H 17/IL-23 axis and neutrophil recruitment in conferring AHR. 39, 45 However, a recent study describes conversion of T H 17 into IFN-g producers in vivo as a prerequisite for AHR, 50 which constitutes a combination of both axes and is conceivable in the light of potential T H 17 cell plasticity. 51 Additional T H plasticity has been observed in patients with allergic airway disease, in whom a subset of IL-17A-secreting T H 2 cells has been detected at increased levels in asthmatic patients and proinflammatory cytokine stimulation was shown to induce IL-17A secretion from classical T H 2 cells. 52 Our studies addressed the role of IL-17A versus IFN-g during the collateral priming process, where we did observe a role for IL-17A but not for IFN-g (Fig 3, D and E) . However, at the present time, we can neither distinguish between a singular contribution of IL-17A versus IFN-g toward the induction of AHR nor exclude a contribution of IL-17A-producing T H 2 cells to collateral priming.
Our findings concerning the role of IL-17A in pulmonary priming might be particularly critical with regard to steroidresistant asthma, which has been described to be mediated by T H 17 cells. 12 Extrapolating from our data, patients with this form of asthma would be at a particular risk for new sensitizations.
Evolutionarily, collateral priming might have evolved to ensure that during an ongoing immune response bystander cells with different antigen specificity could be more easily recruited to become polarized effector cells. At least partially, we draw on this effect when boosting for vaccination to enhance a response against a given pathogen. However, in the context of allergic responses, this beneficial effect can have deleterious consequences because any lung inflammation, regardless of its origin (allergic, viral, and environmental) or polarization, will increase the risk of de novo sensitization toward unrelated harmless antigens. Ultimately, this process leads to polysensitization, a subtype of allergic disease with a much worse clinical course that is immensely more difficult to treat [53] [54] [55] and thus needs to become a focus of future research directions.
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Clinical implications: Our findings bring mechanistic knowledge to the phenomena observed when boostering for vaccination and the phenomenon of polysensitization and primary sensitization in asthma, particularly in the context of concomitant viral infections. 
